New England Journal of Medicine· 2026Q1
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials
- 2citations
- Q1SCImago
- 2026year
Short summary
Oveporexton, an orexin receptor 2 agonist, significantly improved wakefulness, reduced sleepiness, and decreased cataplexy in patients with narcolepsy type 1 over 12 weeks, with mean sleep latency on MWT improving by 14.3-19.8 minutes vs. -0.4 to -0.8 minutes for placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Cognitive Neuroscience
Cognitive NeuroscienceNeuroscience